Market Overview

Mylan Selected As One of the Leading Suppliers to the South African National Department of Health 2013/2014 Antiretroviral Tender


JOHANNESBURG and PITTSBURGH, Nov. 29, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that its subsidiary in India, Mylan Laboratories Ltd., a leading manufacturer of antiretroviral (ARV) drugs, has been selected, through its South African-based subsidiary Mylan (Proprietary) Limited (Mylan Limited), as one of the leading suppliers of ARV drugs to the South African National Department of Health for the tender period January 1, 2013 to December 31, 2014.

Mylan Limited secured a R1.12 billion share, which represents 19.1% of the R5.9 billion tender value. As a part of this award, Mylan will supply the South African Government with 31% of the 30 million units of triple therapy fixed dose combination (FDC) called for in the tender. Mylan is pleased to support the Government's initiative to move to triple therapy FDC treatment regimens in South Africa, as such regimens can simplify treatment and improve patient adherence.

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines, including affordable ARVs. Only through access to these vital medicines can we stem the tide of HIV/AIDS in South Africa and around the world. This award reinforces Mylan's commitment to provide high quality advanced drugs to help people suffering from HIV/AIDS in South Africa, and we are proud to have been selected as a partner to the South African Department of Health."

"We believe Mylan's selection as a leading supplier to the South African Government's ARV tender reflects our vertical integration, quality manufacturing, global scale and proven-track record of being a reliable partner in supplying affordable ARV medicines across the world. We are pleased to bring this global scale, quality and reliability to the South African market and continue our legacy in fighting HIV/AIDS," said Paul Miller, Managing Director and Vice President of Mylan's South African business.

Mylan supplies ARV drugs to more than 120 countries around the world and approximately one-third of HIV/AIDS patients receiving treatment in developing countries depend on a Mylan ARV product. Mylan will be entering the South African market with a comprehensive portfolio of ARV drugs, consisting of first- and second-line adult and pediatric therapies, including several dual and triple FDCs.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside.

SOURCE Mylan Inc.

View Comments and Join the Discussion!